GC has filed a patent for a method to produce a Varicella Zoster Virus surface protein antigen. The method allows for high yield and high purity of the antigen, making it useful for developing vaccines to prevent or treat varicella or herpes zoster. The patent claims a method involving culturing a recombinant cell line and purifying the resulting culture solution. GlobalData’s report on GC gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights GC Corp - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on GC, Personalized cancer vaccines was a key innovation area identified from patents. GC's grant share as of September 2023 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

Method for producing varicella zoster virus surface protein antigen

Source: United States Patent and Trademark Office (USPTO). Credit: GC Corp

A recently filed patent (Publication Number: US20230257718A1) describes a method for producing Varicella Zoster Virus (VZV) surface protein (gE) antigens. The method involves culturing a recombinant cell line that produces the VZV gE antigens and then purifying the culture solution.

The method includes several steps for obtaining and purifying the culture solution. In the culture solution obtaining step, a seed culture is performed on the recombinant cell line, followed by a production culture on the cell line that has undergone the seed culture. The culture solution purifying step involves anion exchange chromatography, hydrophobic interaction chromatography, treatment with a virus-inactivating agent to inactivate viruses, mixed-mode chromatography, and concentration and filtration.

The patent also specifies the amino acid sequence and nucleotide sequence of the VZV gE antigen and the gene used to transform the cell line. The seed culture performing step can be done through subculture, suspension culture, or a combination of both, and the temperature for culturing the cell line during the seed culture and production culture steps is between 34°C and 38°C.

For the anion exchange chromatography step in the culture solution purifying process, a wash buffer with a sodium chloride concentration of 0.1 mM to 150 mM is used, while an elution buffer with a sodium chloride concentration of 400 mM to 600 mM is used. The virus-inactivating agent used is a phosphoric acid solution, and the virus inactivating step is performed under a condition of pH 2.8 to 3.2.

In the final steps of the purification process, a nanofiltration step is performed using a filtration system with a nanofilter. After the nanofiltration step, the filtrate is diluted with a formulation buffer and then filtered again.

Overall, this patent describes a method for producing VZV gE antigens through a series of culturing and purification steps. The method provides specific details on the sequences, temperatures, buffers, and conditions used in each step, ensuring the production of high-quality VZV gE antigens.

To know more about GlobalData’s detailed insights on GC, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies